Serum Homocysteine Level in Parkinson’s Disease and Its Association with Duration, Cardinal Manifestation, and Severity of Disease

Background and Purpose. Due to the high prevalence of Parkinson’s disease (PD) in the elderly, a large financial burden is imposed on the families and health systems of countries in addition to the problems related to the mobility impairment caused by the disease for the patients. Studies on controv...

Full description

Saved in:
Bibliographic Details
Published in:Parkinson's disease 2018-01, Vol.2018 (2018), p.1-6
Main Authors: Khoddami, Azam, Abbaspour, Fatemeh, Firozjaie, Alireza, Samaei, Seyed Ehsan, Ahmadi Ahangar, Alijan, Saadat, Payam, Khafri, Soraya
Format: Article
Language:English
Subjects:
Homocysteine
Medical research
Medicine, Experimental
Physically disabled persons
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c607t-394eb9fc1d3c47676c52a7e0000244242c987f11c02f893cb1f6993b9d551e643
cites cdi_FETCH-LOGICAL-c607t-394eb9fc1d3c47676c52a7e0000244242c987f11c02f893cb1f6993b9d551e643
container_end_page 6
container_issue 2018
container_start_page 1
container_title Parkinson's disease
container_volume 2018
creator Khoddami, Azam
Abbaspour, Fatemeh
Firozjaie, Alireza
Samaei, Seyed Ehsan
Ahmadi Ahangar, Alijan
Saadat, Payam
Khafri, Soraya
description Background and Purpose. Due to the high prevalence of Parkinson’s disease (PD) in the elderly, a large financial burden is imposed on the families and health systems of countries in addition to the problems related to the mobility impairment caused by the disease for the patients. Studies on controversial issues in this disease are taken into consideration, and one of these cases is the role of serum homocysteine level in Parkinson’s patients. In this study, the serum level of homocysteine and its association with various variables in relation to this disease was compared with healthy individuals. Materials and Methods. In this study, 100 patients with PD and 100 healthy individuals as control group were investigated. Serum homocysteine level and demographic and clinical data were included in the checklist. Data were analyzed by SPSS version 23. In all tests, the significance level was below 0.05. Results. The mean level of serum homocysteine in case and control groups was 14.93 ± 8.30 and 11.52 ± 2.86 µmol/L, respectively (95% CI: 1.68; 5.14, P
doi_str_mv 10.1155/2018/5813084
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_121c8c44043e40d185b12b4bc7e8b662</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A586357347</galeid><doaj_id>oai_doaj_org_article_121c8c44043e40d185b12b4bc7e8b662</doaj_id><sourcerecordid>A586357347</sourcerecordid><originalsourceid>FETCH-LOGICAL-c607t-394eb9fc1d3c47676c52a7e0000244242c987f11c02f893cb1f6993b9d551e643</originalsourceid><addsrcrecordid>eNqNkk9rFDEUwAdRbKm9eZaAIILdNn9nkouwbNUurChUzyGTedNNnU1qMtOyNw9-Cb-en8RMd1u74MHJYZKX3_uR5L2ieE7wMSFCnFBM5ImQhGHJHxX7FHM6wVjix-Nc4YnEku0Vhyld4vwxxUTJnhZ7VEnBmeT7xc9ziMMKnYVVsOvUg_OAFnANHXIefTbxm_Mp-N8_fiV06hKYBMj4Bs37hKYpBetM74JHN65fotMh3q6O0MzExnnToY_GuxZSv42PqefZHl2_RqG9Uz4rnrSmS3C4_R8UX9-_-zI7myw-fZjPpouJLXHVT5jiUKvWkoZZXpVVaQU1FYw3o5xTTq2SVUuIxbSVitmatKVSrFaNEARKzg6K-cbbBHOpr6JbmbjWwTh9GwjxQpvYO9uBJpRYaTnHnAHHDZGiJrTmta1A1mVJs-vtxnU11CtoLPg-mm5Hurvj3VJfhGstlOBSsCx4vRXE8H3Ib6RXLlnoOuMhDEnnWiohxqpl9OUGvTD5aM63IRvtiOupkCUTFeNVpo7_QeXRwMrZ4KF1Ob6T8OpBwhJM1y9T6IaxVmkXPNqANoaUIrT31yRYj32oxz7U2z7M-IuHT3MP33VdBt5sgKXzjblx_6mDzEBr_tKU0Hw69gc6Ou2p</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2049550003</pqid></control><display><type>article</type><title>Serum Homocysteine Level in Parkinson’s Disease and Its Association with Duration, Cardinal Manifestation, and Severity of Disease</title><source>Publicly Available Content (ProQuest)</source><source>Wiley Open Access</source><source>PubMed Central</source><creator>Khoddami, Azam ; Abbaspour, Fatemeh ; Firozjaie, Alireza ; Samaei, Seyed Ehsan ; Ahmadi Ahangar, Alijan ; Saadat, Payam ; Khafri, Soraya</creator><contributor>Aasly, Jan</contributor><creatorcontrib>Khoddami, Azam ; Abbaspour, Fatemeh ; Firozjaie, Alireza ; Samaei, Seyed Ehsan ; Ahmadi Ahangar, Alijan ; Saadat, Payam ; Khafri, Soraya ; Aasly, Jan</creatorcontrib><description>Background and Purpose. Due to the high prevalence of Parkinson’s disease (PD) in the elderly, a large financial burden is imposed on the families and health systems of countries in addition to the problems related to the mobility impairment caused by the disease for the patients. Studies on controversial issues in this disease are taken into consideration, and one of these cases is the role of serum homocysteine level in Parkinson’s patients. In this study, the serum level of homocysteine and its association with various variables in relation to this disease was compared with healthy individuals. Materials and Methods. In this study, 100 patients with PD and 100 healthy individuals as control group were investigated. Serum homocysteine level and demographic and clinical data were included in the checklist. Data were analyzed by SPSS version 23. In all tests, the significance level was below 0.05. Results. The mean level of serum homocysteine in case and control groups was 14.93 ± 8.30 and 11.52 ± 2.86 µmol/L, respectively (95% CI: 1.68; 5.14, P&lt;0.001). In total patients, 85 had normal serum homocysteine level, while 15 had high serum homocysteine level. In controls, the homocysteine level was 98 and 2, respectively (P=0.002). In multivariate logistic regression analysis, serum homocysteine level higher than 20 µmol/L was accompanied by 8.64-fold in Parkinson’s disease involvement (95% CI: 1.92; 38.90, P=0.005). Conclusion. Increasing serum homocysteine level elevates the rate to having PD. Serum homocysteine levels did not have any relationship with the duration of the disease, type of cardinal manifestation, and the severity of Parkinson’s disease.</description><identifier>ISSN: 2090-8083</identifier><identifier>EISSN: 2042-0080</identifier><identifier>DOI: 10.1155/2018/5813084</identifier><identifier>PMID: 29854384</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Homocysteine ; Medical research ; Medicine, Experimental ; Physically disabled persons</subject><ispartof>Parkinson's disease, 2018-01, Vol.2018 (2018), p.1-6</ispartof><rights>Copyright © 2018 Payam Saadat et al.</rights><rights>COPYRIGHT 2018 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2018 Payam Saadat et al. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c607t-394eb9fc1d3c47676c52a7e0000244242c987f11c02f893cb1f6993b9d551e643</citedby><cites>FETCH-LOGICAL-c607t-394eb9fc1d3c47676c52a7e0000244242c987f11c02f893cb1f6993b9d551e643</cites><orcidid>0000-0001-7597-9004 ; 0000-0002-2398-7560 ; 0000-0002-3152-7062</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954853/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954853/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,37012,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29854384$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Aasly, Jan</contributor><creatorcontrib>Khoddami, Azam</creatorcontrib><creatorcontrib>Abbaspour, Fatemeh</creatorcontrib><creatorcontrib>Firozjaie, Alireza</creatorcontrib><creatorcontrib>Samaei, Seyed Ehsan</creatorcontrib><creatorcontrib>Ahmadi Ahangar, Alijan</creatorcontrib><creatorcontrib>Saadat, Payam</creatorcontrib><creatorcontrib>Khafri, Soraya</creatorcontrib><title>Serum Homocysteine Level in Parkinson’s Disease and Its Association with Duration, Cardinal Manifestation, and Severity of Disease</title><title>Parkinson's disease</title><addtitle>Parkinsons Dis</addtitle><description>Background and Purpose. Due to the high prevalence of Parkinson’s disease (PD) in the elderly, a large financial burden is imposed on the families and health systems of countries in addition to the problems related to the mobility impairment caused by the disease for the patients. Studies on controversial issues in this disease are taken into consideration, and one of these cases is the role of serum homocysteine level in Parkinson’s patients. In this study, the serum level of homocysteine and its association with various variables in relation to this disease was compared with healthy individuals. Materials and Methods. In this study, 100 patients with PD and 100 healthy individuals as control group were investigated. Serum homocysteine level and demographic and clinical data were included in the checklist. Data were analyzed by SPSS version 23. In all tests, the significance level was below 0.05. Results. The mean level of serum homocysteine in case and control groups was 14.93 ± 8.30 and 11.52 ± 2.86 µmol/L, respectively (95% CI: 1.68; 5.14, P&lt;0.001). In total patients, 85 had normal serum homocysteine level, while 15 had high serum homocysteine level. In controls, the homocysteine level was 98 and 2, respectively (P=0.002). In multivariate logistic regression analysis, serum homocysteine level higher than 20 µmol/L was accompanied by 8.64-fold in Parkinson’s disease involvement (95% CI: 1.92; 38.90, P=0.005). Conclusion. Increasing serum homocysteine level elevates the rate to having PD. Serum homocysteine levels did not have any relationship with the duration of the disease, type of cardinal manifestation, and the severity of Parkinson’s disease.</description><subject>Homocysteine</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Physically disabled persons</subject><issn>2090-8083</issn><issn>2042-0080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqNkk9rFDEUwAdRbKm9eZaAIILdNn9nkouwbNUurChUzyGTedNNnU1qMtOyNw9-Cb-en8RMd1u74MHJYZKX3_uR5L2ieE7wMSFCnFBM5ImQhGHJHxX7FHM6wVjix-Nc4YnEku0Vhyld4vwxxUTJnhZ7VEnBmeT7xc9ziMMKnYVVsOvUg_OAFnANHXIefTbxm_Mp-N8_fiV06hKYBMj4Bs37hKYpBetM74JHN65fotMh3q6O0MzExnnToY_GuxZSv42PqefZHl2_RqG9Uz4rnrSmS3C4_R8UX9-_-zI7myw-fZjPpouJLXHVT5jiUKvWkoZZXpVVaQU1FYw3o5xTTq2SVUuIxbSVitmatKVSrFaNEARKzg6K-cbbBHOpr6JbmbjWwTh9GwjxQpvYO9uBJpRYaTnHnAHHDZGiJrTmta1A1mVJs-vtxnU11CtoLPg-mm5Hurvj3VJfhGstlOBSsCx4vRXE8H3Ib6RXLlnoOuMhDEnnWiohxqpl9OUGvTD5aM63IRvtiOupkCUTFeNVpo7_QeXRwMrZ4KF1Ob6T8OpBwhJM1y9T6IaxVmkXPNqANoaUIrT31yRYj32oxz7U2z7M-IuHT3MP33VdBt5sgKXzjblx_6mDzEBr_tKU0Hw69gc6Ou2p</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Khoddami, Azam</creator><creator>Abbaspour, Fatemeh</creator><creator>Firozjaie, Alireza</creator><creator>Samaei, Seyed Ehsan</creator><creator>Ahmadi Ahangar, Alijan</creator><creator>Saadat, Payam</creator><creator>Khafri, Soraya</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7597-9004</orcidid><orcidid>https://orcid.org/0000-0002-2398-7560</orcidid><orcidid>https://orcid.org/0000-0002-3152-7062</orcidid></search><sort><creationdate>20180101</creationdate><title>Serum Homocysteine Level in Parkinson’s Disease and Its Association with Duration, Cardinal Manifestation, and Severity of Disease</title><author>Khoddami, Azam ; Abbaspour, Fatemeh ; Firozjaie, Alireza ; Samaei, Seyed Ehsan ; Ahmadi Ahangar, Alijan ; Saadat, Payam ; Khafri, Soraya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c607t-394eb9fc1d3c47676c52a7e0000244242c987f11c02f893cb1f6993b9d551e643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Homocysteine</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Physically disabled persons</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khoddami, Azam</creatorcontrib><creatorcontrib>Abbaspour, Fatemeh</creatorcontrib><creatorcontrib>Firozjaie, Alireza</creatorcontrib><creatorcontrib>Samaei, Seyed Ehsan</creatorcontrib><creatorcontrib>Ahmadi Ahangar, Alijan</creatorcontrib><creatorcontrib>Saadat, Payam</creatorcontrib><creatorcontrib>Khafri, Soraya</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Parkinson's disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khoddami, Azam</au><au>Abbaspour, Fatemeh</au><au>Firozjaie, Alireza</au><au>Samaei, Seyed Ehsan</au><au>Ahmadi Ahangar, Alijan</au><au>Saadat, Payam</au><au>Khafri, Soraya</au><au>Aasly, Jan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum Homocysteine Level in Parkinson’s Disease and Its Association with Duration, Cardinal Manifestation, and Severity of Disease</atitle><jtitle>Parkinson's disease</jtitle><addtitle>Parkinsons Dis</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>2018</volume><issue>2018</issue><spage>1</spage><epage>6</epage><pages>1-6</pages><issn>2090-8083</issn><eissn>2042-0080</eissn><abstract>Background and Purpose. Due to the high prevalence of Parkinson’s disease (PD) in the elderly, a large financial burden is imposed on the families and health systems of countries in addition to the problems related to the mobility impairment caused by the disease for the patients. Studies on controversial issues in this disease are taken into consideration, and one of these cases is the role of serum homocysteine level in Parkinson’s patients. In this study, the serum level of homocysteine and its association with various variables in relation to this disease was compared with healthy individuals. Materials and Methods. In this study, 100 patients with PD and 100 healthy individuals as control group were investigated. Serum homocysteine level and demographic and clinical data were included in the checklist. Data were analyzed by SPSS version 23. In all tests, the significance level was below 0.05. Results. The mean level of serum homocysteine in case and control groups was 14.93 ± 8.30 and 11.52 ± 2.86 µmol/L, respectively (95% CI: 1.68; 5.14, P&lt;0.001). In total patients, 85 had normal serum homocysteine level, while 15 had high serum homocysteine level. In controls, the homocysteine level was 98 and 2, respectively (P=0.002). In multivariate logistic regression analysis, serum homocysteine level higher than 20 µmol/L was accompanied by 8.64-fold in Parkinson’s disease involvement (95% CI: 1.92; 38.90, P=0.005). Conclusion. Increasing serum homocysteine level elevates the rate to having PD. Serum homocysteine levels did not have any relationship with the duration of the disease, type of cardinal manifestation, and the severity of Parkinson’s disease.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>29854384</pmid><doi>10.1155/2018/5813084</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-7597-9004</orcidid><orcidid>https://orcid.org/0000-0002-2398-7560</orcidid><orcidid>https://orcid.org/0000-0002-3152-7062</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2090-8083
ispartof Parkinson's disease, 2018-01, Vol.2018 (2018), p.1-6
issn 2090-8083
2042-0080
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_121c8c44043e40d185b12b4bc7e8b662
source Publicly Available Content (ProQuest); Wiley Open Access; PubMed Central
subjects Homocysteine
Medical research
Medicine, Experimental
Physically disabled persons
title Serum Homocysteine Level in Parkinson’s Disease and Its Association with Duration, Cardinal Manifestation, and Severity of Disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A18%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20Homocysteine%20Level%20in%20Parkinson%E2%80%99s%20Disease%20and%20Its%20Association%20with%20Duration,%20Cardinal%20Manifestation,%20and%20Severity%20of%20Disease&rft.jtitle=Parkinson's%20disease&rft.au=Khoddami,%20Azam&rft.date=2018-01-01&rft.volume=2018&rft.issue=2018&rft.spage=1&rft.epage=6&rft.pages=1-6&rft.issn=2090-8083&rft.eissn=2042-0080&rft_id=info:doi/10.1155/2018/5813084&rft_dat=%3Cgale_doaj_%3EA586357347%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c607t-394eb9fc1d3c47676c52a7e0000244242c987f11c02f893cb1f6993b9d551e643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2049550003&rft_id=info:pmid/29854384&rft_galeid=A586357347&rfr_iscdi=true